IRIDEX Corporation — Q1 2016 Form 10-Q
Business and period: IRIDEX develops, manufactures and sells ophthalmic laser systems, delivery devices, consumables, and related services. The company reports one segment. This unaudited quarter ended April 2, 2016 and comprised 13 weeks; comparison is with the 13 weeks ended April 4, 2015.
Financial performance
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Revenue | $11.931 million | $10.796 million |
| Gross profit / margin | $5.297 million / 44.4% | $5.410 million / 50.1% |
| Operating income / margin | $152,000 / 1.2% | $403,000 / 3.7% |
| Net income / diluted EPS | $101,000 / $0.01 | $246,000 / $0.02 |
| Cash provided by operations | $526,000 | $617,000 |
- Revenue grew 10.5%, mainly on international system sales, which increased 30.0% to $4.546 million. Domestic system sales rose 6.3% to $2.212 million. Recurring revenue was approximately flat at $5.173 million.
- Gross margin fell 5.7 percentage points. Management cited introductory Cyclo G6 pricing, product and geographic mix, and lower average selling prices associated with foreign exchange rates.
- Operating expenses were $5.145 million, up from $5.007 million. R&D and sales and marketing increased; general and administrative costs declined. Lower gross profit and higher operating expenses reduced operating and net income.
- Cash and cash equivalents were $10.514 million at quarter-end, versus $9.995 million at January 2, 2016. Working capital was $23.8 million. The company reported no outstanding fixed- or variable-rate debt.
- Quarterly cash flows included $185,000 used in investing activities and $178,000 provided by financing activities. Capital expenditures were $89,000; earn-out payments were $96,000.
Changes, outlook and risks
- International systems sales growth was driven primarily by Asia. China represented 14.4% of revenue, up from 4.9% in the prior-year quarter; the U.S. represented 49.0%, down from 51.7%.
- Management said cash and expected operating cash generation were sufficient to fund operations for the next 12 months. The filing gives no specific revenue or earnings guidance.
- Management expects gross margins to continue fluctuating with geography and product mix, new-product introductions, manufacturing variances, and production volume.
- The company disclosed production and quality difficulties while ramping certain legacy and new products. It reduced shipments, particularly to international distributors, while addressing the issues; unresolved problems could hurt sales and increase costs.
- Contractual obligations totaled $13.410 million: $2.962 million in operating lease payments and $10.448 million in purchase commitments, including $8.034 million due within one year. The company reported no material off-balance-sheet arrangements.
- One customer accounted for 15% of quarterly revenue and approximately 19% of quarter-end receivables. The filing identifies international sales, distributor reliance, competition, regulatory requirements, reimbursement uncertainty, supplier concentration, product quality, and demand variability as risks.
- A $1.7 million grant-date fair value of performance-based restricted stock units for the CEO and five other executives was recorded for compensation over the expected vesting period. The units depend on specified stock-price performance goals and continued service.
Important facts for investors to verify
- Progress and costs in resolving manufacturing and product-quality issues, and whether they continue to constrain shipments.
- Whether Cyclo G6 system sales and related probe demand can grow without continued introductory pricing pressure, and the resulting effect on gross margin.
- International sales mix, particularly Asia and China, and customer concentration in revenue and receivables.
- Cash conversion and liquidity relative to the $8.034 million of purchase commitments due within one year.
- Recoverability of deferred tax assets and changes in the disclosed uncertain tax positions; the filing reports $8.985 million of deferred income taxes and $0.9 million of unrecognized tax benefits as of the stated periods.